Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.54 |
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | NAMPT | P43490 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ESRRG | P62508 | 3/20 | 0.47 |
| ▸ | ESRRB | O95718 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | NQO2 | P16083 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | F13A1 | P00488 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL379892 | 0.88 | CA2 (0.54) | CA2CA1NAMPTMAPTSMN1; SMN2 | |
| SCHEMBL7808431 | 0.87 | CA2 (0.56) | CA2CA1NAMPTMAPTALDH1A1 | |
| SCHEMBL1936202 | 0.87 | MGLL (0.55) | CA2CA1NAMPTMAPTALDH1A1 | |
| SCHEMBL2511243 | 0.85 | CA2 (0.55) | CA2CA1NAMPTMAPTSMN1; SMN2 | |
| SCHEMBL12511497 | 0.85 | CA2 (0.52) | CA2CA1NAMPTMAPTSMN1; SMN2 | |
| SCHEMBL27741035 | 0.84 | CA2 (0.56) | CA2CA1NAMPTMAPTSMN1; SMN2 | |
| SCHEMBL12283041 | 0.84 | NPC1 (0.60) | CA2CA1NAMPTMAPTSMN1; SMN2 | |
| SCHEMBL100146 | 0.84 | KDM4E (0.60) | CA2CA1NAMPTMAPTSMN1; SMN2 | |
| SCHEMBL1569661 | 0.84 | CA2 (0.56) | CA2CA1NAMPTMAPTSMN1; SMN2 | |
| SCHEMBL8127981 | 0.84 | EPHX2 (0.59) | CA2CA1NAMPTMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4368184-A2 | NOVEL COMPOUNDS FOR THE DIAGNOSIS, TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH THE AGGREGATION OF ALPHA-SYNUCLEIN | Modag GmbH (DE) | 2024-05-15 | — | — | EP | disclosed |
| US-20230067910-A1 | NOVEL COMPOUNDS FOR THE DIAGNOSIS, TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH THE AGGREGATION OF ALPHA-SYNUCLEIN | MODAG GMBH (DE) | 2023-03-02 | — | — | US | disclosed |
| EP-4061807-A1 | NOVEL COMPOUNDS FOR THE DIAGNOSIS, TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH THE AGGREGATION OF ALPHA-SYNUCLEIN | Modag GmbH (DE) | 2022-09-28 | — | — | EP | disclosed |
| US-7601868-B2 | Such as 4-(cyclopropylmethoxy)-N-(2-{4-[1-(1-pyrrolidinyl)ethyl]phenyl}ethyl)benzamide having melanin-concentrating hormone antagonistic action, for prophylaxis and/or treatment of obesity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-13 | — | — | US | disclosed |
| US-20060128690-A1 | Amine derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1593667-A1 | AMINE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2005-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230067910-A1 | NOVEL COMPOUNDS FOR THE DIAGNOSIS, TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH THE AGGREGATION OF ALPHA-SYNUCLEIN | SNCA, PARK7, SYNCRIP | CA2 3599/4885CA1 3948/4885NAMPT 3741/4885 |
| US-20060128690-A1 | Amine derivative | MC1R, MC2R, MC4R | CA2 3719/4885CA1 4236/4885NAMPT 3153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.